Actively Recruiting
Phase 2 Study of Safety and Immune Response to a New Inhaled COVID-19 Vaccine in Adults Aged 18 to 65
Led by McMaster University · Updated on 2026-01-26
350
Participants Needed
2
Research Sites
4 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety and immune response of a new inhaled COVID-19 vaccine called ChAd-triCoVMac. This vaccine is designed to improve lung mucosal immunity, which current vaccines do not adequately induce, especially against evolving variants. The study focuses on adults aged 18 to 65 who have already received at least three doses of an mRNA COVID vaccine and are generally healthy. Participants will be randomly assigned to receive either the experimental inhaled vaccine or a placebo. The vaccine dose is given as a fine mist inhaled directly into the lungs using a nebulizer. Some participants will also undergo a bronchoscopy to collect lung cells four weeks after vaccination. The study includes a placebo-controlled design with careful monitoring of immune responses and safety. During the study, participants will attend clinic visits for checkups and blood tests at 2, 4, and 8 weeks after vaccination. They will report any symptoms for 24 weeks. Researchers will measure specific T cell responses in blood and lung samples, antibody levels, and any adverse events possibly related to the vaccine. The study will help predict vaccine efficacy and guide future vaccine development. Total follow-up lasts 24 weeks after vaccination.
CONDITIONS
Brief Title
A Trial of a Next Generation COVID-19 Vaccine Delivered by Inhaled Aerosol
Research Team
M
Marilyn Swinton
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
